FilingReader Intelligence

GNI Group updates 2025 outlook amid tariff concerns

April 8, 2025 at 12:02 PM UTCBy FilingReader AI

GNI Group (TSE:2160) has issued an update on its financial forecast for the fiscal year ending December 2025, factoring in the effects of recently announced US tariff policies. The company maintains strong growth expectations for its pharmaceutical segment, projecting revenue of JPY20,202 million and operating income of JPY4,640 million. The drug discovery segment anticipates revenue of JPY955 million and operating income of JPY3,982 million. The medical technology segment faces challenges, with potential operating profit reductions of JPY9 million to JPY15 million depending on tariff rates imposed on goods imported from China. The "Other" segment anticipates revenue of JPY1,525 million and operating income of JPY16,314 million due to listing gains of Cullgen.

This report was generated by FilingReader's AI system from regulatory filings and company disclosures. To request a correction, contact editorial@filingreader.com

TSE:2160Tokyo Stock Exchange

News Alerts

Get instant email alerts when Gni Group publishes news

Free account required • Unsubscribe anytime

Filing Activity Timeline

View Complete Filing History →